Stryker (SYK) Expected to Announce Quarterly Earnings on Tuesday

Stryker (NYSE:SYK) will likely be issuing its quarterly earnings data after the market closes on Tuesday, January 28th. Analysts expect the company to announce earnings of $3.87 per share and revenue of $6,358,730.00 billion for the quarter. Stryker has set its FY 2024 guidance at 12.000-12.100 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect Stryker to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Stryker Trading Up 0.6 %

Shares of Stryker stock opened at $383.91 on Tuesday. The stock has a market capitalization of $146.35 billion, a P/E ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95. Stryker has a 52-week low of $307.23 and a 52-week high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock’s 50-day simple moving average is $375.51 and its 200 day simple moving average is $359.17.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is 36.01%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Citigroup lifted their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reissued an “outperform” rating and set a $425.00 price objective on shares of Stryker in a report on Tuesday, January 7th. Robert W. Baird lifted their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, BTIG Research upped their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.